Yüksel Ürün: Our comment about ‘Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer’
Yüksel Ürün shared on X:
“Our comment about ‘Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer’.
Congrats Omar El-Taji et al. for this comprehensive M-A.
Novel androgen receptor signaling inhibitors (ARSI) have revolutionized prostate cancer treatment but pose cardiovascular (CV) risks.
Key Findings:
ARSI increases the risk of all-grade CV events and severe CV events.
Notable risks include hypertension, ACS, cardiac dysrhythmia, cerebrovascular events, and CV-related death.
Mechanism and Side Effects:
Abiraterone Acetate: Different action mechanism compared to AR antagonists, affecting cardiovascular system due to mineralocorticoid precursor production.
AR Antagonists: Distinct drug-drug interaction profiles and cardiovascular impact.
Study Suggestion:
Evaluation of Abiraterone and AR antagonists as separate subgroups for a clearer understanding of their distinct side effect profiles.”
Read further.
Source: Yüksel Ürün/X
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023